Available Trials

Anal Cancer

Breast Cancer

  • USOR 17188

    High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

    Available at 5 locations

  • STAR14059

    HER2 Amplified Metastatic Breast Cancer

    Available at 8 locations

  • USOR18109

    All Pathologies/Patients

    Available at 7 locations

  • USOR17079

    Clinical Data to Evaluate New Gene Expression Profiles (A Registry), All Comers Applicable

    Available at 7 locations

  • USOR 17009

    HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer (ER+/PR+/HER2- )

    Available at 7 locations

  • USOR 16128

    ER+/HER2- Breast Cancer

    Available at 7 locations

Endometrial Cancer

  • USOR 17197

    Advanced Endometrial Cancer

    Available at 7 locations

Gastric

  • STAR 18016

    Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

    Available at 8 locations

Head and Neck

  • USOR 17132

    Advanced Squamous Cell Carcinoma of the Head and Neck

    Available at 6 locations

Leukemia

  • AZA-MDS-006

    Myelodysplastic syndromes (MDS) or Acute Myeloid Leukemia (AML) on Bone Marrow

    Available at 6 locations

Lung Cancer

  • STAR 18164

    Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors with RET fusion

    Available at 8 locations

  • STAR 18129

    Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

    Available at 8 locations

  • STAR 18076

    Stage IIIB (locally advanced or recurrent and not a candidate for curative therapy) or stage IV Advanced Non–Small-Cell Lung Cancer

    Available at 8 locations

  • STAR 17143

    Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation

    Available at 8 locations

  • USOR18109

    All Pathologies/Patients

    Available at 7 locations

  • USOR 17199

    Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

    Available at 7 locations

  • USOR 17167

    Non-Small Cell Lung Cancer, stages II-IIIA and IIIB (T>5cm N2) completely resected (R0)

    Available at 4 locations

  • USOR 16156

    Non-Small Cell Lung Cancer High Tumor Mutation Burden

    Available at 7 locations

Lymphoma

  • USOR18109

    All Pathologies/Patients

    Available at 7 locations

  • STAR 16248

    Follicular Lymphoma with EZH2 mutation

    Available at 8 locations

  • STAR 11282

    Hodkin Lymphoma (HL) in Adults Age 60 and Above

    Available at 8 locations

  • USOR 16065

    Follicular Lymphoma, Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma

    Available at 7 locations

Multiple Myeloma

  • USOR 16035

    Multiple Myeloma

    Available at 7 locations

Myelofibrosis

  • STAR 17085

    Myelofibrosis, post-poycythemia vera myelofibrosis, post essential thrombocytopenia myelo fibrosis

    Available at 8 locations

Neutropenia

  • USOR18109

    All Pathologies/Patients

    Available at 7 locations

Ovarian Cancer

Pancreatic Cancer

Prostate Cancer

  • STAR 16238

    Metastatic Castration-resistant Prostate Cancer (mCRPC) with BRCA1/2 mutation or ATM

    Available at 8 locations

  • USOR 18128

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Available at 8 locations

  • USOR18109

    All Pathologies/Patients

    Available at 7 locations

  • STAR 16237

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Available at 8 locations

Renal Cancer

  • USOR 16251

    Renal Cell Carcinoma Clear Cell Component

    Available at 6 locations

  • USOR 16145

    Clear Renal Cell Carcinoma

    Available at 7 locations

Skin Cancer

Solid Tumors

  • STAR 18164

    Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors with RET fusion

    Available at 8 locations

  • STAR 16248

    Follicular Lymphoma with EZH2 mutation

    Available at 8 locations

Rare Malignancies

Urothelial Cancer

  • USOR 18283

    urothelial or non-urothelial carcinoma of the urinary tract

    Available at 7 locations

  • STAR 15228

    Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

    Available at 8 locations

  • USOR 17005

    Advanced or Metastatic Urothelial Cancer

    Available at 6 locations